¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ½ÃÀå : ÀÀ¿ë ºÐ¾ßº°, ÇÕ¼º Á¦Ç° À¯Çüº°, ÇÕ¼º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå À¯Çüº°, »ç¾÷ ±Ô¸ðº°, Ä¡·á ºÐ¾ßº°, ÃÖÁ¾»ç¿ëÀÚº°, ±â¾÷ ±Ô¸ðº°, Áö¿ªº° : »ê¾÷ µ¿Çâ ¹× ¼¼°è ¿¹Ãø(-2035³â)
Oligonucleotide Synthesis Market by Application Area, Type of Product Synthesized, Type of Oligonucleotide Synthesized, Scale of Operation, Therapeutic Area, End-Users, Company Size and Regions: Industry Trends and Global Forecasts, Till 2035
»óǰÄÚµå : 1616875
¸®¼­Ä¡»ç : Roots Analysis
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 325 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,799 £Ü 6,810,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,999 £Ü 9,932,000
PDF (One-Location Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ Æ¯Á¤ »ç¾÷ ºÎ¹®¿¡ ¼ÓÇÑ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,599 £Ü 15,041,000
PDF (Department License) help
PDF º¸°í¼­¸¦ ºÎ¼­ ´ÜÀ§·Î 12¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,999 £Ü 25,542,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å ÇÕ¼º ½ÃÀå ±Ô¸ð´Â 2035³â±îÁö ¿¹Ãø ±â°£ µ¿¾È 9.9%ÀÇ CAGR·Î È®´ëµÇ¾î ÇöÀç 48¾ï ´Þ·¯¿¡¼­ 2035³â±îÁö 135¾ï ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å´Â Á¦¾à »ê¾÷¿¡¼­ °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÐ¾ß Áß ÇϳªÀÔ´Ï´Ù. ÀÌ ºÐÀÚµéÀº ¿¬±¸, À¯ÀüÀÚ °Ë»ç, ¹ýÀÇÇÐ ºÐ¼® ¹× ±âŸ ºÐ¼® ¹æ¹ý°ú °°Àº ´Ù¾çÇÑ ¿ëµµ·Î ¹ÙÀÌ¿ÀÀǾàǰ ¹× »ý¸í°øÇÐ ºÐ¾ß¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÇöÀç ¿¬±¸ÀÚµéÀº ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵尡 ¼ö¸¹Àº Áúº´ ÀûÀÀÁõ Ä¡·á¸¦ À§ÇÑ ¾à¸®ÇÐÀû Á¢±Ù¹ýÀÌ µÉ ¼ö ÀÖ´Â °¡´É¼ºÀ» ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ä¡·á ¸ñÀûÀ¸·Î ´Ù¾çÇÑ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå¸¦ Æò°¡Çϱâ À§ÇØ ¿©·¯ Áö¿ª¿¡¼­ °ÅÀÇ 300°³ÀÇ ÀÓ»ó½ÃÇèÀÌ µî·ÏµÇ¾î ÀÖ´Ù´Â Á¡Àº ÁÖ¸ñÇÒ ¸¸ÇÕ´Ï´Ù. ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å Á¦Á¶ »ê¾÷ÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å Ä¡·áÁ¦ÀÇ °³¹ß ¹× »ý»êÀ» À§ÇÑ ´ë±Ô¸ð »ý»ê¿¡ ¼ö¸¹Àº ÀÚµ¿ ¿Ã¸®°í ÇÕ¼º ±â°è°¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÕ¼º±â´Â ºÐÀÚ ÇÕ¼º, º¸È£±â Á¦°Å, Á¤Á¦, Å»¿°, µ¿°á°ÇÁ¶ µîÀÇ ´Ü°è¸¦ È¿À²ÀûÀ¸·Î ¼öÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀÌµå »ý»ê°ú °ü·ÃµÈ °úÁ¦´Â °³¹ß ±â°£ÀÇ Àå±âÈ­, Á¤Á¦ ±â¼ú ºÎÁ·, Àü¹® Áö½Ä ºÎÁ·, °³¹ßÀÚÀÇ ±ÔÁ¦ ¹× ÄÄÇöóÀ̾𽺠°ü·Ã ¹®Á¦ µîÀ¸·Î ÀÎÇØ ÀǾàǰ °³¹ß ±â¾÷Àº ÁÖ¿ä ¾÷¹«¸¦ ¾Æ¿ô¼Ò½ÌÇÏ´Â Ãß¼¼ÀÔ´Ï´Ù. ÇöÀç 110°³ ÀÌ»óÀÇ ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å ÇÕ¼º °ø±Þ¾÷ü°¡ ¿¬±¸, Áø´Ü, Ä¡·á¿ë ¸ÂÃãÇü ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å ÇÕ¼º, ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀÌµå º¯Çü, ¿Ã¸®°í´ºÅ¬·¹¿ÀŸÀ̵å Á¤Á¦ ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ±â¹Ý ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀÇ ¼ºÀå, À¯¸ÁÇÑ ÀÓ»ó½ÃÇè °á°ú, ÀÌ ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸ Ȱµ¿Àº ¿¹Ãø ±â°£ µ¿¾È ¸ÂÃãÇü/À§Å¹ ¼­ºñ½º Á¦°ø¾÷ü¿¡°Ô À¯¸®ÇÑ ½ÃÀå ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ÀÀ¿ë ºÐ¾ßº°, ÇÕ¼º Á¦Ç° À¯Çüº°, ÇÕ¼º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå À¯Çüº°, »ç¾÷ ±Ô¸ðº°, Ä¡·á ºÐ¾ßº°, ÃÖÁ¾»ç¿ëÀÚº°, ±â¾÷ ±Ô¸ðº°, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÀÔ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼Ò°³

Á¦4Àå ½ÃÀå »óȲ : ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Á¦Á¶(Á¶»ç ¹× Áø´Ü ¿ëµµ)

Á¦5Àå ½ÃÀå »óȲ : ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Á¦Á¶¾÷ü(Ä¡·á ¿ëµµ)

Á¦6Àå ±â¾÷ °æÀï·Â ºÐ¼® : ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Á¦Á¶(¿¬±¸ ¹× Áø´Ü ¿ëµµ)

Á¦7Àå ±â¾÷ °æÀï·Â ºÐ¼® : ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Á¦Á¶¾÷ü(Ä¡·á ¿ëµµ)

Á¦8Àå ±â¾÷ °³¿ä : ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Á¦Á¶¾÷ü(¿¬±¸ ¹× Áø´Ü ¿ëµµ)

Á¦9Àå ±â¾÷ °³¿ä : ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Á¦Á¶¾÷ü(Ä¡·á ¿ëµµ)

Á¦10Àå Á¦Á¶Àΰ¡ ±¸ÀÔÀΰ¡ ÀÇ»ç ÀÇ»ç°áÁ¤ ÇÁ·¹ÀÓ¿öÅ©

Á¦11Àå ´ëÇü Á¦¾àȸ»çÀÇ ´ëó

Á¦12Àå ÆÄÆ®³Ê½Ê°ú Çù¾÷

Á¦13Àå ÃÖ±ÙÀÇ È®Àå

Á¦14Àå ÆÄÆ®³Ê Èĺ¸ ºÐ¼®

Á¦15Àå ÀÓ»ó½ÃÇè ºÐ¼®

Á¦16Àå ¿ë·® ºÐ¼®

Á¦17Àå ¼ö¿ä ºÐ¼®

Á¦18Àå ½ÃÀå ±Ô¸ð Æò°¡¿Í ±âȸ ºÐ¼®

Á¦19Àå COVID-19 ÆÒµ¥¹ÍÀÌ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦20Àå SWOT ºÐ¼®

Á¦21Àå Á¶»ç ºÐ¼®

Á¦22Àå À̱×Á¦Å¥Æ¼ºê ÀλçÀÌÆ®

Á¦23Àå °á·Ð

Á¦24Àå ºÎ·Ï 1 : Ç¥Çü½Ä µ¥ÀÌÅÍ

Á¦25Àå ºÎ·Ï 2 : ±â¾÷¡¤´Üü ¸®½ºÆ®

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

OLIGONUCLEOTIDE SYNTHESIS MARKET: OVERVIEW

As per Roots Analysis, the global oligonucleotide synthesis market is estimated to grow from USD 4.8 billion in the current year to USD 13.5 billion by 2035, at a CAGR of 9.9% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Application Area

Type of Product Synthesized

Type of Oligonucleotide Synthesized

Scale of Operation

Therapeutic Area

End-users

Company Size

Key Geographical Regions

OLIGONUCLEOTIDE SYNTHESIS MARKET: GROWTH AND TRENDS

Oligonucleotides are one of the fastest growing segments in the pharmaceutical industry. These molecules are extensively utilized in biopharmaceutical and biotechnology fields for various applications, including research, genetic testing, forensic analysis, and other analytical methods. Currently, researchers are investigating the potential of oligonucleotides as a pharmacological approach for the treatment of a myriad of disease indications. In addition, it is worth noting that close to 300 clinical trials have been registered across different geographical regions to evaluate various oligonucleotides for therapeutic purposes. As the oligonucleotide manufacturing industry advances, numerous automatic oligo synthesizers are being incorporated into large scale production for developing and producing oligonucleotide therapeutics. These synthesizers can execute steps, such as molecule synthesis, removal of protecting groups, purification, desalting and lyophilization, with increased efficiency. However, the challenges associated with oligonucleotide production, including extended timelines, lack of purification techniques, lack of expertise, and regulatory and compliance-related issues among the developers, have driven drug developers to outsource key operations. At present, over 110 oligonucleotide synthesis providers offer custom oligonucleotide synthesis, oligonucleotide modification and oligonucleotide purification services, which are intended for research, diagnostic and therapeutic applications. The growing oligonucleotide-based drugs pipeline, encouraging clinical trial results and extensive research activity in the domain, is likely to present lucrative market growth opportunities for custom / contract service providers, during the forecast period.

OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY INSIGHTS

The report delves into the current state of the oligonucleotide synthesis market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Presently, over 110 synthesis providers claim to have the necessary capabilities to offer oligonucleotide synthesis services; the majority of these firms are based in North America.

2. Stakeholders in this domain synthesize various types of oligonucleotides, across different scales of operations; close to 90% of the players offer purification services.

3. In pursuit of building a competitive edge in this field, stakeholders are actively upgrading their existing capabilities and adding new competencies in order to enhance their respective portfolios.

4. Close to 300 clinical trials (with over 75,000 enrolled patients) have been registered to investigate oligonucleotide based-therapeutic products, across different geographies.

5. Since 2017, several deals have been inked between various stakeholders engaged in this domain; acquisitions emerged as the most common type of partnership model.

6. To keep pace with the growing demand for oligonucleotides, companies have made elaborate investments to expand their existing capacities and capabilities; this trend is most pronounced in the US and China.

7. Several big pharma players have undertaken various initiatives, including partnerships, expansions and funding initiatives; 48% of such initiatives were focused on the development and manufacturing of RNAi oligonucleotides.

8. The global, installed oligonucleotide synthesis capacity is spread across various geographies; interestingly, more than 75% of the total capacity is installed at the facilities owned by large and very large players.

9. Given the growing complexity of APIs, the demand for oligonucleotides has upsurged; by 2035, it is anticipated to reach around 2,200 kilograms, across clinical and commercial scales.

10. Considering the wide array of applications of oligonucleotides and the continuous research efforts of stakeholders in this domain, the adoption of these modalities is poised to witness steady growth in the foreseeable future.

11. Driven by the increasing number of chronic indications (requiring novel personalized therapies) and ongoing research on oligonucleotide-based therapeutics, this market is anticipated to grow at a CAGR of 9.9%, till 2035.

12. Over 40% of the market is expected to be captured by revenues generated from manufacturing drugs for rare diseases; further, oligonucleotide synthesis market in China is likely to grow at a faster pace.

OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY SEGMENTS

Currently, the Oligonucleotide Finished Dosage Form holds the Largest Share of the Oligonucleotide Synthesis Market

Based on the type of product synthesized, the market is segmented into active pharmaceutical ingredients and finished dosage forms. It is worth highlighting that the majority of the current oligonucleotide synthesis market is captured by oligonucleotide finished dosage form and this trend is likely to remain same in the coming decade.

Antisense Oligonucleotide is Likely to Dominate the Oligonucleotide Synthesis Market During the Forecast Period

Based on the type of oligonucleotide synthesized, the market is segmented into antisense, DNA, siRNA and other oligonucleotides. It is worth highlighting that siRNA and antisense oligonucleotides-based therapies are likely to grow at a relatively higher CAGR, during the forecast period. This can be attributed to the rising number of approved siRNA and antisense oligonucleotides-based therapies for various rare diseases, genetic disorders and other disorders.

By Scale of Operation, Commercial Scale is Likely to Capture the Larger Share of the Oligonucleotide Synthesis Market During the Forecast Period

Based on scales of operation, the market is segmented into clinical and commercial scale. It is worth highlighting that the commercial scale manufacturing will be the primary driver of the overall market in the coming decade.

Currently, Pharmaceutical and Biopharmaceutical Companies hold the Largest Share within the Oligonucleotide Synthesis Market

Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, academic and research institutes, and hospitals. It is worth highlighting that the revenues generated from manufacturing of oligonucleotides by pharmaceutical and biopharmaceutical companies is expected to grow substantially in the coming decade as compared to other end-users.

By Company Size, Mid-Sized Companies are Likely to Grow at a Relatively Higher Pace During the Forecast Period

Based on company size, the market is segmented into small, mid-sized, and large and very large companies. It is worth highlighting that the majority of the current oligonucleotide synthesis market is captured by large and very large players.

Rare Diseases Segment Accounts for the Largest Share for the Oligonucleotide Synthesis Market

Based on therapeutic areas, the market is segmented into cardiovascular disorders, genetic disorders, liver disorders, rare diseases and other disorders. While rare diseases account for a relatively higher market share, it is worth highlighting that cardiovascular disorders segment is expected to witness substantial market growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. It is worth highlighting that over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Oligonucleotide Synthesis Market

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

OLIGONUCLEOTIDE SYNTHESIS MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS)

5. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)

6. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURES (RESEARCH AND DIAGNOSTIC APPLICATIONS)

7. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)

8. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (RESEARCH AND DIAGNOSTIC APPLICATIONS)

9. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)

10. MAKE VERSUS BUY DECISION FRAMEWORK

11. BIG PHARMA INITIATIVES

12. PARTNERSHIPS AND COLLABORATIONS

13. RECENT EXPANSIONS

14. LIKELY PARTNER ANALYSIS

15. CLINICAL TRIAL ANALYSIS

16. CAPACITY ANALYSIS

17. DEMAND ANALYSIS

18. MARKET SIZING AND OPPORTUNITY ANALYSIS

19. IMPACT OF COVID-19 PANDEMIC ON OLIGONUCLEOTIDE SYNTHESIS MARKET

20. SWOT ANALYSIS

21. SURVEY ANALYSIS

22. EXECUTIVE INSIGHTS

23. CONCLUDING REMARKS

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â